Items where authors include "Lamoureux, F."

Article

Gartland, A. orcid.org/0000-0002-3712-2437, Pasello, M., Lézot, F. et al. (1 more author) (2023) Editorial: New therapies in the treatment of sarcomas. Frontiers in Endocrinology, 14. 1137736. ISSN 1664-2392

Moukengue, B., Brown, H.K., Charrier, C. et al. (11 more authors) (2020) TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model. EBioMedicine, 53. 102704. ISSN 2352-3964

Marino, S., de Ridder, D., Bishop, R.T. et al. (14 more authors) (2019) Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice. EBioMedicine, 44. pp. 452-466. ISSN 2352-3964

Tellez-Gabriel, M., Ory, B., Lamoureux, F. et al. (2 more authors) (2016) Tumour heterogeneity: the key advantages of single-cell analysis. International Journal of Molecular Sciences, 17 (12). 2142. ISSN 1661-6596

Rodriguez Calleja, L., Jacques, C., Lamoureux, F. et al. (13 more authors) (2016) ΔNp63α silences a microRNA program to aberrantly initiate a wound healing program that promotes TGFβ-induced metastasis. Cancer Research, 76 (11). pp. 3236-3251. ISSN 0008-5472

Ory, B., Baud'huin, M.E., Verrecchia, F. et al. (7 more authors) (2016) Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression. Clinical Cancer Research, 22 (10). pp. 2520-2533. ISSN 1078-0432

Jacques, C., Lamoureux, F., Baud'huin, M. et al. (8 more authors) (2016) Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1. Oncotarget. ISSN 1949-2553

Jacques , C., Rodriguez-Calleja, L., Baud'huin, M. et al. (4 more authors) (2016) miRNA-193a-5p of p73 controls cisplatin chemoresistance in primary bone tumors. Oncotarget, 7. pp. 54503-54514. ISSN 1949-2553

Gobin, B., Baud'Huin, M., Lamoureux, F. et al. (8 more authors) (2015) BYL719, a new alpha-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. International Journal of Cancer, 136 (4). pp. 784-796. ISSN 0020-7136

Lamoureux, F., Baud'huin, M., Ory, B. et al. (5 more authors) (2014) Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. Oncotarget, 5 (17). pp. 7805-7819. ISSN 1949-2553

Odri, G., Kim, P-P., Lamoureux, F. et al. (6 more authors) (2014) Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration. BMC Cancer, 14. 169. ISSN 1471-2407

Lamoureux, F., Baud'huin, M., Calleja, L.R. et al. (7 more authors) (2014) Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. NATURE COMMUNICATIONS, 5. ARTN 3511. ISSN 2041-1723

Baud'huin, M.E., Duplomb, L., Teletchea, S. et al. (6 more authors) (2013) Osteoprotegerin: multiple partners for multiple functions. Cytokine and Growth Factor Reviews, 24 (5). pp. 401-409. ISSN 1359-6101

Picarda, G., Matous, E., Amiaud, J. et al. (8 more authors) (2013) Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL. Journal of Bone Oncology, 2 (3). pp. 95-104. ISSN 2212-1374

Rousseau, J., Escriou, V., Lamoureux, F. et al. (8 more authors) (2011) Formulated siRNAs Targeting Rankl Prevent Osteolysis and Enhance Chemotherapeutic Response in Osteosarcoma Models. Journal of Bone and Mineral Research, 26 (10). pp. 2452-2462. ISSN 0884-0431

Odri, G.A., Dumoucel, S., Picarda, G. et al. (10 more authors) (2010) Zoledronic Acid as a New Adjuvant Therapeutic Strategy for Ewing's Sarcoma Patients. Cancer Research, 70 (19). pp. 7610-7619. ISSN 0008-5472

Picarda, G., Lamoureux, F., Geffroy, L. et al. (7 more authors) (2010) Preclinical Evidence that Use of TRAIL in Ewing's Sarcoma and Osteosarcoma Therapy Inhibits Tumor Growth, Prevents Osteolysis, and Increases Animal Survival. Clinical Cancer Research, 16 (8). pp. 2363-2374. ISSN 1078-0432

Lamoureux, F., Picarda, G., Garrigue-Antar, L. et al. (7 more authors) (2009) Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma. Cancer Research, 69 (2). pp. 526-536. ISSN 0008-5472

Chauvin, C., Philippeau, J-M., Hemont, C. et al. (7 more authors) (2008) Killer Dendritic Cells Link Innate and Adaptive Immunity against Established Osteosarcoma in Rats. Cancer Research, 68 (22). pp. 9433-9440. ISSN 0008-5472

Brounais, B., Ruiz, C., Rousseau, J. et al. (4 more authors) (2008) Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption. Recent Patents on Anti-Cancer Drug Discovery, 3 (3). pp. 178-186. ISSN 1574-8928

Lamoureux, F., Picarda, G., Rousseau, J. et al. (6 more authors) (2008) Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Molecular Cancer Therapeutics, 7 (10). pp. 3389-3398. ISSN 1535-7163

Lamoureux, F., Ory, B., Battaglia, S. et al. (6 more authors) (2008) Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid. International Journal of Cancer, 122 (4). pp. 751-760. ISSN 0020-7136

Lamoureux, F., Richard, P., Wittrant, Y. et al. (8 more authors) (2007) Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: Blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Research, 67 (15). pp. 7308-7318. ISSN 0008-5472

Lamoureux, F., Baud'huin, M., Duplomb, L. et al. (2 more authors) (2007) Proteoglycans: key partners in bone cell biology. BioEssays, 29 (8). pp. 758-771. ISSN 0265-9247

Wittrant, Y., Lamoureux, F., Mori, K. et al. (4 more authors) (2006) RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. International Journal of Oncology, 28 (1). pp. 261-269. ISSN 1019-6439